AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22086352 — intervention group
Group type: EXPERIMENTAL
Intervention: Separable stimuli (pictures with easily discriminable features)
Number of subjects: 0
Study 21902684 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone (low or high doses)
Number of subjects: 445
Study 18239240 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal supplement
Number of subjects: 80
Study 18239240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 16627774 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsupine positions (sitting, squatting, or kneeling/hands-and-knees)
Number of subjects: 198
Study 16627774 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 198
Study 14709298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics
Number of subjects: 60
Study 14709298 — intervention group
Group type: COMPARATOR
Intervention: Topical mydriatics
Number of subjects: 60
Study 10942063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 80 mg/m2
Number of subjects: 12
Study 10942063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 60 mg/m2
Number of subjects: 12
Study 10942063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 70 mg/m2
Number of subjects: 12
Study 10942063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine (all doses)
Number of subjects: 12
Study 10942063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 12
Study 8782844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg twice a day)
Number of subjects: 16
Study 8782844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1619943 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC 12 mg/m2 intravenously on day 1 and OK‐432 5 KE intradermally on days 6, 8, and 11
Number of subjects: 15
Study 1619943 — intervention group
Group type: COMPARATOR
Intervention: MMC 12 mg/m2 alone followed by long‐term tegafur
Number of subjects: 15
Study 3927756 — intervention group
Group type: EXPERIMENTAL
Intervention: WIC prenatal participation
Number of subjects: 7628
Study 3927756 — intervention group
Group type: COMPARATOR
Intervention: Non-WIC comparison group
Number of subjects: 7628
Study 31272483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative computed tomography (IOCT)
Number of subjects: 0
Study 31272483 — intervention group
Group type: COMPARATOR
Intervention: Preoperative computed tomography (POCT)
Number of subjects: 0
Study 31272483 — intervention group
Group type: EXPERIMENTAL
Intervention: IOCT
Number of subjects: 0
Study 31272483 — intervention group
Group type: COMPARATOR
Intervention: POCT
Number of subjects: 0
Study 30470229 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d combined with ezetimibe 10 mg/d (A20E10 group, n=48)
Number of subjects: 98
Study 30470229 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/d (A40 group, n=50)
Number of subjects: 98
Study 27798770 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg SOFE (50 mg hydroxytyrosol)
Number of subjects: 36
Study 27798770 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg SOFE (100 mg hydroxytyrosol)
Number of subjects: 36
Study 27798770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25086401 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee arthroscopy combined with a structured exercise programme (surgery group)
Number of subjects: 150
Study 25086401 — intervention group
Group type: COMPARATOR
Intervention: Structured exercise programme alone (non-surgery group)
Number of subjects: 150
Study 22151023 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 0
Study 22151023 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 0
Study 22151023 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 0
Study 22151023 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 0
Study 20610550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (3 cycles of 5 minutes of ischemia alternating with 5 minutes of reperfusion)
Number of subjects: 30
Study 20610550 — intervention group
Group type: COMPARATOR
Intervention: Lower limb ischemia-reperfusion (tourniquet application)
Number of subjects: 30
Study 18250251 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (100 mg) with medical management (MM) alone
Number of subjects: 604
Study 18250251 — intervention group
Group type: COMPARATOR
Intervention: Placebo with medical management (MM) alone
Number of subjects: 604
Study 18250251 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (100 mg) with combined behavioral intervention (CBI)
Number of subjects: 604
Study 18250251 — intervention group
Group type: COMPARATOR
Intervention: Placebo with combined behavioral intervention (CBI)
Number of subjects: 604
Study 15718356 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+ARA from fish/fungal oil (DHA+ARA(FF))
Number of subjects: 60
Study 15718356 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+ARA from egg/fish oil (DHA+ARA(EF))
Number of subjects: 60
Study 15718356 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 60
Study 11901961 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects were given the actual probabilities
Number of subjects: 200
Study 11901961 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects were told if they did well they could leave early
Number of subjects: 200
Study 11901961 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 11901961 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition condition
Number of subjects: 200
Study 11901961 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects were asked to recommend a strategy for another subject
Number of subjects: 200
Study 10216805 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (200‐300 mg b.i.d.)
Number of subjects: 528
Study 10216805 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5‐20 mg o.d.)
Number of subjects: 528
Study 8801328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapress 240 (formulation A) single dose (240 mg)
Number of subjects: 2
Study 8801328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapress 240 (formulation A) multiple dose (240 mg qd for 6 days)
Number of subjects: 2
Study 8801328 — intervention group
Group type: COMPARATOR
Intervention: Cardizem CD (formulation B)
Number of subjects: 2
Study 8801328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapress 240 (formulation A) single dose (240 mg) without subject 8
Number of subjects: 2
Study 8801328 — intervention group
Group type: COMPARATOR
Intervention: Dilapress 240 (formulation A) and Cardizem CD (formulation B)
Number of subjects: 2
Study 2196146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (up to 1.5 mg/kg/day)
Number of subjects: 31
Study 2196146 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (up to 3.0 mg/kg/day)
Number of subjects: 31
Study 2196146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Dextroamphetamine and Methylphenidate
Number of subjects: 31
Study 2196146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg oral dose before anaesthesia
Number of subjects: 46
Study 31103 — intervention group
Group type: COMPARATOR
Intervention: Control group (37 patients)
Number of subjects: 46
Study 31310855 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban plus aspirin
Number of subjects: 7392
Study 31310855 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (apixaban, thienopyridine, and aspirin)
Number of subjects: 7392
Study 31310855 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (apixaban plus aspirin)
Number of subjects: 7392
Study 31310855 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI major/minor bleeding
Number of subjects: 7392
Study 28615090 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling during OGTT after rest
Number of subjects: 10
Study 28615090 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling during OGTT after exercise
Number of subjects: 10
Study 28615090 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling for ISIMatsuda after rest
Number of subjects: 10
Study 28615090 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling for ISIMatsuda after exercise
Number of subjects: 10
Study 28615090 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling for ISICederholm after rest
Number of subjects: 10
Study 28615090 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling for ISICederholm after exercise
Number of subjects: 10
Study 28615090 — intervention group
Group type: COMPARATOR
Intervention: Venous blood sampling
Number of subjects: 10
Study 25439604 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 114
Study 25439604 — intervention group
Group type: COMPARATOR
Intervention: Contact lens (CL) correction
Number of subjects: 114
Study 24107881 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial group therapy (PST) for 3 months
Number of subjects: 0
Study 24107881 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial group therapy (PST)
Number of subjects: 0
Study 22075098 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram plus placebo
Number of subjects: 665
Study 22075098 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion sustained release (SR) plus escitalopram
Number of subjects: 665
Study 22075098 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine extended release (XR) plus mirtazapine
Number of subjects: 665
Study 22075098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment specified)
Number of subjects: 665
Study 20209977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-assisted anesthesia (AAA) group: electroacupuncture (EA, 2 Hz/100 Hz, 9 mA) applied to Changqiang (GV 1) and Yaoshu (GV 2) for 20 min, and 1% lidocaine (5 mL) injected into GV 1.
Number of subjects: 40
Study 20209977 — intervention group
Group type: COMPARATOR
Intervention: Control group: 20 mL and 10 mL of 1% lidocaine injected into GV 2 and GV 1, respectively.
Number of subjects: 40
Study 16978077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus metronidazole
Number of subjects: 531
Study 16978077 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus metronidazole
Number of subjects: 531
Study 16978077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 531
Study 15531054 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella alta group during fast walking
Number of subjects: 24
Study 15531054 — intervention group
Group type: COMPARATOR
Intervention: Pain-free controls during fast walking
Number of subjects: 24
Study 15531054 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella alta group during normal walking
Number of subjects: 24
Study 15531054 — intervention group
Group type: COMPARATOR
Intervention: Pain-free controls during normal walking
Number of subjects: 24
Study 11551092 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach clinics
Number of subjects: 324
Study 11551092 — intervention group
Group type: COMPARATOR
Intervention: Main base clinics
Number of subjects: 324
Study 10196816 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior-inferior mandibular osteotomy
Number of subjects: 10
Study 10196816 — intervention group
Group type: COMPARATOR
Intervention: Somnographic registration (apnea index, apnea/hypopnea index, oxygen desaturation index) and cephalometric analysis
Number of subjects: 10
Study 8001520 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of slow release ascorbic acid, 100 micrograms of organic selenium, 200 mg of D‐alpha‐tocopheryl acetate and 30 mg of beta‐carotene daily for 3 months
Number of subjects: 40
Study 8001520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3042874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (initial dose, 3 mg/kg; total, 11.4 mg/kg per 48 h)
Number of subjects: 38
Study 3042874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3042874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 38
Study 30915444 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of α- and β-carotene
Number of subjects: 5488
Study 30915444 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of lutein plus zeaxanthin (L + Z)
Number of subjects: 5488
Study 30915444 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of α-tocopherol
Number of subjects: 5488
Study 28370447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (45 mg/10 mg twice daily)
Number of subjects: 13
Study 28370447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 25452049 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine or hydromorphone
Number of subjects: 139
Study 23276118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness self-training intervention group
Number of subjects: 283
Study 23276118 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 283
Study 21740445 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma irradiation (60 Gy in daily increments of 2 Gy)
Number of subjects: 60
Study 21740445 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin restoration
Number of subjects: 60
Study 21740445 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restoration
Number of subjects: 60
Study 21740445 — intervention group
Group type: COMPARATOR
Intervention: Nonirradiated teeth
Number of subjects: 60
Study 18556080 — intervention group
Group type: COMPARATOR
Intervention: 8 Gy in single fraction
Number of subjects: 160
Study 18556080 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy in 10 fractions
Number of subjects: 160
Study 16607109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralow-dose transdermal estradiol at 0.014 mg/d
Number of subjects: 417
Study 16607109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 14682655 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalate desensitizing agent
Number of subjects: 87
Study 14682655 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 87
Study 10953672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal-based foods (chapatti, idli, poori) containing 50 g carbohydrate
Number of subjects: 0
Study 10953672 — intervention group
Group type: COMPARATOR
Intervention: Reference glucose load (50 g)
Number of subjects: 0
Study 10953672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal-based foods (GI values)
Number of subjects: 0
Study 10953672 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro starch digestibility
Number of subjects: 0
Study 9317197 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 0
Study 9317197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8363067 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia followed by intravenous morphine (GA)
Number of subjects: 95
Study 8363067 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia followed by epidural fentanyl (RA)
Number of subjects: 95
Study 8363067 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 95
Study 8363067 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (RA)
Number of subjects: 95
Study 8363067 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GA and RA)
Number of subjects: 95
Study 8363067 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed postoperative arterial thrombosis
Number of subjects: 95
Study 3539618 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 15 mg i.v. + 50 mg q.i.d. orally
Number of subjects: 22
Study 3539618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30120066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobitolimod
Number of subjects: 104
Study 30120066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 28318397 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-macronutrient shake
Number of subjects: 0
Study 28318397 — intervention group
Group type: COMPARATOR
Intervention: Fasting period of 8 hours
Number of subjects: 0
Study 26550787 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone scan with SPECT/CT
Number of subjects: 80
Study 26550787 — intervention group
Group type: COMPARATOR
Intervention: Control group (diagnostic blocks based on clinical diagnosis)
Number of subjects: 80
Study 24320469 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed automatic localization algorithm using weighted Hough transform and constrained probabilistic boosting tree
Number of subjects: 0
Study 24320469 — intervention group
Group type: COMPARATOR
Intervention: Manual measurements
Number of subjects: 0
Study 20205349 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed dye laser (LPDL)
Number of subjects: 40
Study 20205349 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 40
Study 18418017 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT)
Number of subjects: 32
Study 18418017 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiochemotherapy (RCT)
Number of subjects: 32
Study 16830315 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 16
Study 16830315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12028324 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Number of subjects: 2676
Study 12028324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2676
Study 10494048 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (Li; 31 patients)
Number of subjects: 59
Study 10494048 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ; 28 patients)
Number of subjects: 59
Study 8983620 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 103
Study 8983620 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 103
Study 8983620 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tolerance
Number of subjects: 103
Study 8983620 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasovagal reactions
Number of subjects: 103
Study 1837931 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg nebulized ipratropium bromide
Number of subjects: 32
Study 1837931 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg nebulized ipratropium bromide
Number of subjects: 32
Study 1837931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline (5 mg) administered 2 hours after ipratropium
Number of subjects: 32
Study 7026254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 20 mg
Number of subjects: 46
Study 7026254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 60 mg
Number of subjects: 46
Study 7026254 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 50 mg
Number of subjects: 46
Study 30776295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led preventive, complex psychological intervention (promotion of a therapeutic ICU environment, 3 stress support sessions, relaxation and recovery program)
Number of subjects: 1458
Study 30776295 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1458
Study 30776295 — intervention group
Group type: COMPARATOR
Intervention: Nurse-led preventive, complex psychological intervention vs. usual care
Number of subjects: 1458
Study 28277402 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation algorithm (RA)
Number of subjects: 48
Study 28277402 — intervention group
Group type: COMPARATOR
Intervention: General rehabilitation protocol (RP)
Number of subjects: 48
Study 26854974 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg
Number of subjects: 204
Study 26854974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 24320560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg
Number of subjects: 100
Study 24320560 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 μg/kg
Number of subjects: 100
Study 22044044 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidants (AOs) treatment with α‐lipoic acid at 400 mg/day in association with genistein and vitamins
Number of subjects: 32
Study 22044044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19387424 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5‐1.8 mg/kg per day)
Number of subjects: 265
Study 19387424 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine responders
Number of subjects: 265
Study 19387424 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cohort of ADHD children
Number of subjects: 265
Study 19387424 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian subgroup
Number of subjects: 265
Study 17204208 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 24
Study 17204208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) and interferon
Number of subjects: 24
Study 17204208 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 24
Study 12903414 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative phenoxybenzamine (group P)
Number of subjects: 80
Study 12903414 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (group N)
Number of subjects: 80
Study 12903414 — intervention group
Group type: EXPERIMENTAL
Intervention: Both phenoxybenzamine and neostigmine (group U)
Number of subjects: 80
Study 12903414 — intervention group
Group type: COMPARATOR
Intervention: Control group (without drugs)
Number of subjects: 80
Study 12903414 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (when urinary retention happened)
Number of subjects: 80